Fecal Microbiota Transplantation Via Capsules Relieves Ulcerative Colitis by Improving Gut Microbiota and Serum Metabolites

Hongzhi Xu,Qiongyun Chen,Yanyun Fan,Bangzhou Zhang,Changsheng Yan,Qiang Zhang,Yuhao Ke,Zhangran Chen,Lin Wang,Huaxiu Shi,Yiqun Hu,Qingwen Huang,Jingling Su,Chenxi Xie,Xu Zhang,Lixiang Zhou,Jianlin Ren
DOI: https://doi.org/10.21203/rs.3.rs-1606914/v1
2022-01-01
Abstract:Abstract BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) is a therapy that can induce clinical remission in ulcerative colitis. FMT through enema or colonoscopy brings pain to patients. In this study, we aimed to assess the efficiency of FMT via capsules in UC and determine the specific factors related to the response to clinical remission. METHODS We conducted a single-blind trial in Zhongshan Hospital of Xiamen University, China. 21 patients were randomized to accept FMT, and 4 were assigned to the placebo. Patients in the FMT group received capsules filled with healthy donor fecal material and those in the placebo group received capsules filled with glycerol. We performed 16s ribosomal RNA gene sequencing and shotgun metagenomics in fecal samples and analyzed serum samples for metabolome features. RESULTS FMT via capsules could receive favorable levels of therapeutic success in UC. 3 FMTs in 1 week induced clinical remission in 57.1% (12 of 21) and clinical response in 76.2% (16 of 21). Gut bacterial richness after FMT was increased in the patients who achieved remission. The increased relative abundance of Alistipes sp, O. splanchnicus, and F. prausnitzii was the strongest predictor of clinical remission. Patients in remission after FMT had enrichment of Alistipes sp, O. splanchnicus and had increased levels of indolelactic acid. Patients who did not achieve remission had enrichment of Escherichia coli and Klebsiella and increased levels of 12,13-DiHOME and lipopolysaccharide biosynthesis. CONCLUSIONS We had demonstrated the efficacy of FMT via capsules in active UC. We found that FMT could promote gut microbiome reconstruction, reduce the invasion of harmful bacteria and the synthesis of LPS, and accelerate the metabolism of indoleacetic acid by increasing the abundance of specific bacteria to alleviate intestinal inflammation. These findings may raise a new way in the design of FMT therapy for UC. ClinicalTrails.gov (NCT03426683).
What problem does this paper attempt to address?